DermTech Announces Proposed Public Offering of Common Stock

Rhea-AI Summary

DermTech, Inc. (Nasdaq: DMTK) announced a proposed underwritten public offering of its common stock. The company plans to grant underwriters a 30-day option to purchase an additional 15% of the shares sold. Proceeds from the offering will fund commercialization of clinical tests, accelerate pipeline development, and cover general corporate purposes. Cowen and William Blair are the joint book-running managers. The offering is subject to market conditions, and a preliminary prospectus will be available at the SEC’s website.

Positive

• Proceeds from the offering will support commercialization and pipeline development.
• DermTech is leveraging a strong non-invasive skin genomics platform.

Negative

• Market conditions may affect the completion or terms of the offering.
• Potential shareholder dilution due to the public offering.

DermTech, Inc. (Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that it has commenced a proposed underwritten public offering of its common stock. In connection with the offering, DermTech intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the offering. All of the shares in the offering will be sold by DermTech. DermTech currently intends to use the net proceeds from the offering to fund further commercialization of its clinical commercial tests, accelerate pipeline development and for general corporate purposes, including working capital and other general and administrative purposes.

Cowen and William Blair are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

The offering will be made only by means of a written prospectus and related prospectus supplement forming part of DermTech’s shelf registration statement on Form S-3 (File No. 333-248642) that was filed with the Securities and Exchange Commission (the “SEC”) on September 8, 2020 and declared effective by the SEC on September 17, 2020. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be available at the SEC’s website located at www.sec.gov. Alternatively, copies may be obtained from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by email at PostSaleManualRequests@broadridge.com or by telephone at (833) 297-2926, or from William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by email at prospectus@williamblair.com or by telephone at 1-800-621-0687. Before you invest, you should read the prospectus supplement and the accompanying prospectus along with other documents that DermTech has filed with the SEC for more complete information about DermTech and the offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About DermTech:

DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments.

Forward-Looking Statements:

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the intention, completion, timing and option relating to the proposed public offering and the intended use of proceeds therefrom, as well as the performance, patient benefits, cost-effectiveness, commercialization and adoption of DermTech’s products and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; (9) uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all; and (10) other risks and uncertainties included in the “Risk Factors” section of the preliminary prospectus available on the SEC’s website located at www.sec.gov, the most recent Quarterly Report on Form 10‑Q filed by DermTech with the SEC, and other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210106005815/en/

FAQ

What is the purpose of DermTech's proposed public offering of common stock?

The offering aims to fund commercialization of clinical tests and accelerate pipeline development.

Who are the underwriters for DermTech's public offering?

Cowen and William Blair are acting as joint book-running managers for the offering.

What is the size of DermTech's public offering?

The exact size of the offering is not disclosed, but underwriters have a 30-day option to purchase an additional 15% of shares sold.

How will the proceeds from the DermTech offering be used?

Proceeds will be used for commercialization of clinical tests, pipeline development, and general corporate purposes.

What risks are associated with DermTech's public offering?

Market conditions may impact the completion and terms of the offering, and there is a risk of shareholder dilution.